The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study | Zendy

Yuxiang Ma | Zendy; Shuang Xin | Zendy; Qingguang Lin | Zendy; Wei Zhuang | Zendy; Yuanyuan Zhao | Zendy; Xia Zhu | Zendy; Hongyun Zhao | Zendy; Min Huang | Zendy; Xun Xu | Zendy; Yunpeng Yang | Zendy; Wenfeng Fang | Zendy; Li Zhang | Zendy; Xueding Wang | Zendy

Open Access

The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study

Author(s) -

Yuxiang Ma,

Shuang Xin,

Qingguang Lin,

Wei Zhuang,

Yuanyuan Zhao,

Xia Zhu,

Hongyun Zhao,

Min Huang,

Xun Xu,

Yunpeng Yang,

Wenfeng Fang,

Li Zhang,

Xueding Wang

Publication year - 2019

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2019.12.60

Subject(s) - medicine , gefitinib , pharmacokinetics , lung cancer , oncology , pharmacology , single nucleotide polymorphism , genotype , gastroenterology , cancer , biology , epidermal growth factor receptor , gene , biochemistry

The C of gefitinib was significantly different between and genotypes, but not with the efficacy of gefitinib treatment. rs2032582 and rs10256836 polymorphisms were correlated treatment outcome. Polymorphisms analysis of could be a predictive biomarker for gefitinib treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research